Business news

    Zelira Therapeutics (ASX:ZLD) raises A$1.77M from US-based investors

    Article Image

    Zelira Therapeutics (ASX:ZLD) has announced a successful direct capital raise of A$1.77M from US-based investors to provide additional working capital for further progressing its strategies and FDA clinical trials.

    Zelira Therapeutics is a global biopharmaceutical company that researches, develops and commercialises clinically validated cannabinoid-based medicines.

    The company says it owns a portfolio of proprietary revenue-generating products, as well as a pipeline of candidates undergoing clinical development.

    Zelira Therapeutics also says it generates revenue from two proprietary medications, HOPEĀ® and ZENIVOLĀ®.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa